Leqembi clinical trials are still ongoing, and participants have a 50/50 chance of receiving the $26,500-per-year drug for free. The other half will receive…
When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it…
Certain medications and health factors could increase your risk of side effects when taking LEQEMBI™ and other monoclonal antibody drugs for Alzheimer’s. Here’s what…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…